Desmoid tumors (DT) are rare, non-metastatic soft tissue tumors that arise from fibroblasts and can be locally aggressive. They account for approximately 3-5 cases per million people annually. With the increasing focus on developing better therapies, the desmoid tumor drug pipeline is expanding, offering promising treatment options. The growing emphasis on personalized medicine and improved therapeutic products is expected to enhance patient outcomes and fuel market growth, addressing the unmet medical needs in desmoid tumor management.
Major companies involved in the desmoid tumors pipeline drugs market include Immunome, Inc., SpringWorks Therapeutics, Inc., and others.
Leading drugs currently in the pipeline include AL102, Nirogacestat, and others.
Advancements in targeted therapies, increased research on novel drug candidates, and a rising focus on personalized treatment approaches are driving the growth of the desmoid tumors drug pipeline.
The Desmoid Tumors Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into desmoid tumors therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for desmoid tumors. The desmoid tumors report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The desmoid tumors pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with desmoid tumors treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to desmoid tumors.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Desmoid tumors are rare, non-cancerous growths that develop in connective tissues, often in the abdomen, arms, legs, or chest. They arise due to mutations in the CTNNB1 gene or from conditions like familial adenomatous polyposis (FAP). Although benign, they can infiltrate surrounding tissues, causing pain and functional impairment. Trauma, surgery, or hormonal factors may trigger their growth.
Desmoid tumors are treated through a multidisciplinary approach. Treatment options include active surveillance for slow-growing tumors, surgery for resectable cases, and radiation therapy for inoperable tumors. Systemic therapies, such as anti-hormonal drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), or targeted therapies like tyrosine kinase inhibitors, are used for aggressive or recurrent tumors. Treatment choice depends on tumor size, location, and progression.
The global incidence of desmoid tumors (DT) is approximately 3-5 cases per million person-years, with the highest frequency in adults aged 20-44 years, particularly women. In the United States, around 1,000 new cases are diagnosed annually, with 90% linked to mutations in the β-catenin gene (CTNNB1). In Europe, the incidence is 3 cases per million person-years, with women affected 2.2–3.9 times more than men.
This section of the report covers the analysis of desmoid tumors drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total desmoid tumors clinical trials.
The drug molecule categories covered under the desmoid tumors pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and biologics. The desmoid tumors report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for desmoid tumors.
The EMR report for the desmoid tumors drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed desmoid tumors therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in desmoid tumors clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Desmoid Tumors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of desmoid tumors drug candidates.
AL102, sponsored by Immunome, Inc., is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase II/III RINGSIDE trial for progressive desmoid tumors. The study aims to assess the efficacy and safety of AL102. This potential once-daily oral treatment shows promise in being more effective than OGSIVEO™ (nirogacestat), the first FDA-approved therapy for desmoid tumors.
Nirogacestat, sponsored by Stanford University, is currently being studied in a Phase II trial for desmoid tumors. The objective is to evaluate the efficacy of systemic oral Nirogacestat combined with Cryoablation. Patients receive Nirogacestat for three cycles (28 days each), followed by cryoablation, and continue treatment through 26 cycles over 24 months, assessing disease progression, pain relief, and quality of life.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Desmoid Tumors Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for desmoid tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into desmoid tumors collaborations, regulatory environments, and potential growth opportunities.
Soft Tissue Sarcoma Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share